hero image
C. Michael  White, Pharm.D., FCP, FCCP - University of Connecticut. Storrs, CT, US

C. Michael White, Pharm.D., FCP, FCCP C. Michael  White, Pharm.D., FCP, FCCP

Head and Distinguished Professor, Department of Pharmacy Practice | University of Connecticut


Dr. White’s research interests are in drug, dietary supplement, and illicit drug safety, quality, and cost


Dr. White is the co-director of the Health Outcomes, Policy, and Evidence Synthesis (HOPES) research group and has authored over 400 research articles with over 12,320 citations and an h-Index of 59 (top 5% of all researchers for impact of work) including sentinel work in JAMA, Lancet, Annals of Internal Medicine, Circulation, Journal of the American College of Cardiology, Diabetes Care, and many others. His research interests are in the areas of comparative effectiveness, and preventing adverse events from drugs, devices, herbs, and illicit substances. Dr. White has received major media coverage by TV (NBC Nightly News, Good Morning America, Today Show, Dr Oz Show, BBC & CBC, PBS News Hour, CNN, MSNBC), newspaper (New York Times, Washington Post, Boston Globe, LA Times, Chicago Tribune), radio (WNPR, CBS Radio Network, Bloomberg Radio, SiriusXM, Colin McEnroe Show), and magazine/online (Vogue, The Scientist, Newsweek, The Conversation, Salon, Huffington Post, Inverse) media outlets among many others. Many of his publications have an Almetric score over 200, showing major uptake by major media outlets, and several were among the top three most read articles in the journal in the preceding year (Annals Pharmacotherapy, Journal of Clinical Pharmacology, Oral Diseases). He is an ACCP Young Investigator of the Year, AACP Lyman Award Winner, ASHP Sustained Contribution to the Literature (lifetime achievement award), and five time ASHP Foundation Drug Therapy Research Award recipient. He has a recurring TV segment called Ask the Pharmacist on Fox61 and a book entitled The Part-Time Diet. He is a University Teaching Fellow and a BOT Distinguished Professor, the highest designation for teaching and overall excellence bestowed by the University of Connecticut. Dr. White is also a Fellow of the American College of Clinical Pharmacologists and The American College of Clinical Pharmacy.

Areas of Expertise (8)



Drug Costs

Dietary Supplements

Cardiovascular Drugs

Drugs of Abuse

Opioids and Kratom

Drug Safety

Education (3)

UConn School of Pharmacy/Hartford Hospital: Fellowship, Pharmacy 1998

Albany College of Pharmacy: Pharm.D, Pharmacy 1996

Albany College of Pharmacy: B.S., Pharmacy 1994

Affiliations (2)

  • Fellow of American College of Clinical Pharmacy and American College of Clinical Pharmacologists
  • Member of American heart Association and American Society of Health System Pharmacists







Dieting is Killing your Diet  Stange but True! Source UConn School of Pharmacy What to know about insomnia, sleeplessness and sleeping pills


Media Appearances (14)

Everyone — including Trump — has an opinion about this potential COVID-19 treatment, and that’s making it hard to find out if it works

Boston Globe  print


Not only were the study designs flawed, the findings were contradictory. Some found no effect, some linked the drug to bad outcomes, including death, and a few found positive effects.

“We know that it’s not poison. People have taken it for a long period of time,'' said C. Michael White, another author of the review and head of UConn’s Department of Pharmacy Practice. “But we can’t say the benefits are going to be worth those risks because we can’t say there’s any benefit.”

view more

Hydroxychloroquine: What we know, what we don't know

Fox61  tv


Doctor Michael White of the UConn School of Pharmacy knows the drug well, he was part of a group that just finished a comprehensive review of studies on hydroxychloroquine. He said the interest in the drug was understandable, especially given the urgency of the situation.

“One of the things that was really attractive about it was that it was relatively inexpensive and manufacturers were already making it so the chance that they would be able to gear up and have adequate supply of the drug, over a relatively short period of time, was high,” he said.

view more

Weighing the Cardiac Risks of Hydroxychloroquine

Infectious Disease Special Edition  online


However, since the French study was published, it has been the subject of heavy scrutiny. Because of such questions, the International Society of Antimicrobial Chemotherapy, which publishes the journal where the paper appeared, has flagged the paper, saying it did not meet its “expected standard."

“The take-home message is that it is not clear whether or not hydroxychloroquine with or without azithromycin reduces hospitalization duration, hastens [patients] becoming virus free, or prevents clinical deterioration and how safe the use of hydroxychloroquine with or without azithromycin is in patients with COVID-19 infection,” said C. Michael White, PharmD, the department head and a professor of pharmacy practice at the University of Connecticut School of Pharmacy, in Storrs.

view more

The Kratom Debate: Helpful Herb Or Dangerous Drug?

NPR  radio


"The data to support either the benefits or the harms for kratom is really, really poor," says C. Michael White, head of the Department of Pharmacy Practice at the University of Connecticut. "A lot of the information we have comes from single-case reports."

White says that animal studies suggest kratom could be an effective pain reliever, but the collection of human data has only just begun. He says scientists need to conduct a lot more research before the appropriate level of regulation is clear.

view more

Serious Concerns Raised Over FDA’s Capacity to Inspect Overseas Drug Makers

FairWarning  online


The United States is more reliant than ever on other countries for its supply of pharmaceutical drugs. According to the FDA, roughly 40 percent of finished drugs and 80 percent of active drug ingredients are made overseas. The FDA is tasked with regularly inspecting drug manufacturing facilities in the U.S. and abroad to ensure they’re following best practices.

“We’ve created a scenario where we don’t have the capacity to make a lot of those products in the U.S.,” said C. Michael White, head of the Department of Pharmacy Practice at the University of Connecticut. “We’ve concentrated them in areas where we have very little control, and very little knowledge of what they’re doing.”

view more

Kratom Is a Lifesaver, Say Opioid Addicts. But Its Safety Is Questionable

KQED  radio


“The data to support either the benefits or the harms for kratom is really, really poor," said C. Michael White, head of the Department of Pharmacy Practice at the University of Connecticut. "A lot of the information we have comes from single-case reports."

White says animal studies suggest kratom could be an effective pain reliever but that the collection of human data has only just begun. He says scientists need to conduct a lot more research before the appropriate level of regulation is clear.

view more

Should You Be Worried About the Latest Drug Recall?

Medium  online


“NDMA is in virtually all municipal water supplies to some extent,” says C. Michael White, a professor at the University of Connecticut School of Pharmacy. As it turns out, NDMA is a product of water treatment, and levels of up to 0.1 microgram per liter in drinking water are considered acceptable, according to the World Health Organization. It is even present in some of the food we eat, especially smoked products and processed grilled meat, such as bacon and burgers.

view more

Trump administration reveals plan to import certain prescription drugs from Canada

Daily News  online


Though the general consensus is that imported drugs would be less expensive, there are varying opinions on the safety of prescription drugs that come from other countries.

"Importing drugs in this particular way cripples the patient-pharmacist relationship that is an important link in the medication safety chain and compromises the ability of the pharmacist to relay important information back to the prescribers," C. Michael White, PharmD, of the department of pharmacy practice at the University of Connecticut, said in an earlier interview. "In addition, this type of imported drug could be coming from a variety of sources and being mailed in from several countries, compromising the ability to detect and mitigate drug interactions or to provide medication therapy management."

view more

Smart Pills Help Monitor Cancer Patients’ Therapy

The Scientist  online


University of Connecticut pharmacist Charles White, who is not involved with the program, notes that the pills could provide doctors with valuable data about when a patient isn’t sticking to a treatment regimen—and why. Patients may not adhere to their treatment regimens for many reasons: they may have so many drugs to take that they cannot recall which ones they have taken, they may not understand why they need certain drugs, or they may not want to suffer the side effects associated with a treatment. “Sometimes it is a conscious choice,” White says. There may also be financial constraints; the patient may not fill the prescription because they can’t afford the copay. White says that smart pills could help start the conversation among patients, physicians, and pharmacists about these obstacles.

view more

Drug Researchers Raise Concern Over "Misleading" Evidence in Kratom Studies

Inverse  online


A February paper in Clinical Toxicology showed a rising number of calls to poison control centers for kratom, but as Inverse reported, without knowing how many people are using kratom, it’s impossible to know the likelihood of an adverse event like the ones reported in Eggleston’s study.

“An important new finding would be that the calls to poison control centers from 2017 to 2018 is continuing to rise, but does this indicate that kratom is becoming more risky over time or that more people are using it and the overall risk is still low?” C. Michael White, Pharm.D., a professor of pharmacy practice at the University of Connecticut who studies kratom and was not involved with the study, tells Inverse.

view more

Calls to poison control centers from Kratom have risen, but why?

FOX61  online


“One of the things that’s likely playing a role is that, up until a couple of years ago, virtually no one had heard of Kratom,” said Dr. Michael White, from the UConn School of Pharmacy. He said it’s possible that many past problems with Kratom went overlooked or underreported because many people didn’t know what it is.

view more

Health Watch: What is CBD oil used for?

FOX61  online


So, where does the latest science stand? Dr. Michael White, from the UConn School of Pharmacy, said human studies are still few and far between, but there have been many more studies done on animals.

“In single-cell studies and in animal studies [CBD oil has shown] that it can reduce pain, that it has an anti-anxiety effect, that it can reduce sebum production and it has an anti-inflammatory effect,” said Dr. White.

view more

Opinion: What Jeff Sessions doesn’t understand about medical marijuana

MarketWatch  online


On Jan. 4, Attorney General Jeff Sessions rescinded the Cole memo, a 2013 document that limits federal enforcement of marijuana laws.

This opens the door for a crackdown in the nine states with legal recreational marijuana.

view more

Should Kratom Be Banned?

Dr. Oz  tv


Pharmacist Charles Michael White discusses the current research and anecdotes on kratom. Then, Hamilton Morris, host of “Hamilton’s Pharmacopeia”, weighs in on the controversy and Dr. Oz shares his final thoughts.

view more

Articles (13)

Hydroxychloroquine for COVID-19: A new review of several studies shows flaws in research and no benefit The Conversation


President Donald Trump revealed on May 18, 2020 that he was taking hydroxychloroquine to prevent contracting COVID-19. News media reports run the gamut from saying hydroxychloroquine is 91% effective to it being both ineffective and dangerous. How do people know what to believe?

view more

No, CBD is not a miracle molecule that can cure coronavirus, just as it won’t cure many other maladies its proponents claim The Conversation


The claims for CBD’s alleged healing powers have been so exaggerated that it’s no surprise that a CBD maker was recently warned by the New York attorney general for claiming that the molecule can fight COVID-19. There are no credible animal or human studies showing CBD has any effect on SARS-CoV-2 or the course of COVID-19 infection.

As professor and chair of the Department of Pharmacy Practice at the University of Connecticut, I’ve investigated many claims of vitamin cures for various illnesses over the decades, including CBD.

view more

Natural supplements can be dangerously contaminated, or not even have the specified ingredients The Conversation


More than two-thirds of Americans take dietary supplements. The vast majority of consumers – 84% – are confident the products are safe and effective.

They should not be so trusting.

I’m a professor of pharmacy practice at the University of Connecticut. As described in my new article in the Annals of Pharmacotherapy, consumers take real risks if they use diet supplements not independently verified by reputable outside labs.

view more

Why your generic drugs may not be safe and the FDA may be too lax The Conversation


Generic prescription drugs have saved the U.S. about US $1.7 trillion over the past decade. The Food and Drug Administration approved a record 781 new generics in 2018 alone, including generic versions of Cialis, Levitra and Lyrica. They join generic versions of blockbusters from yesteryear, like Lipitor, Nexium, Prozac and Xanax.

Seniors are the biggest purchasers of generics, because they take the most medications and are on fixed incomes, but virtually everyone has taken a generic antibiotic or pain pill at one time.

This leads to a vital question: Are generics safe?

view more

Generic Drugs Not as Safe as FDA Wants You to Believe Annals of Pharmacotherapy


Food and Drug Administration (FDA) rules for the production of prescription drugs are very rigorous and, if followed, guarantees a safe drug supply. For many years, foreign manufacturers have produced substandard generic products and active pharmaceutical ingredients and shipped them into the United States.

view more

Understanding and Preventing (N-Nitrosodimethylamine) NDMA Contamination of Medications Annals of Pharmacotherapy


N-nitrosodimethylamine (NDMA) is a hepatotoxic agent and carcinogen contaminant in commonly used medications such as valsartan, losartan, irbesartan, and ranitidine. NDMA can be produced during manufacture, introduced from contaminated ingredients procured elsewhere, or introduced from contaminated solvents and catalysts.

view more

Loperamide: A Readily Available but Dangerous Opioid Substitute The Journal of Clinical Psychology

C. Michael White


The antidiarrheal over‐the‐counter drug loperamide is increasingly being used to control opioid withdrawal or for opioid abuse. Taking many times above the normally recommended dose is dangerous with cardiovascular, respiratory, and neurological adverse events.

view more

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential The Journal of Clinical Psychology

C. Michael White


Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA)‐approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.

view more

Impact of a Perioperative Prophylaxis Guideline on Post–Cardiothoracic Surgery Atrial Fibrillation Annals of Pharmacotherapy

Rosanna Li, C Michael White, Jola Mehmeti, Spencer T Martin, Laura C Hobbs


National practice guidelines do not provide clear recommendations on combination pharmacological regimens to reduce cardiothoracic surgery (CTS) postoperative atrial fibrillation (POAF). Objective: This study examines if there is a reduction in POAF rates after implementing a perioperative prophylaxis guideline that includes amiodarone, β-blockers, and high-intensity statins.

view more

The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids Journal of Clinical Pharmacology

C. Michael White


This article presents information on illicitly used synthetic cannabinoids. Synthetic cannabinoids are structurally heterogeneous and commonly used drugs of abuse that act as full agonists of the cannabinoid type-1 receptor but have a variety of additional pharmacologic effects. There are numerous cases of patient harm and death in the United States, Europe, and Australia with many psychological, neurological, cardiovascular, pulmonary, and renal adverse events.

view more

Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation Annals of Pharmacotherapy

C Michael White, Elaine Nguyen


Objective: To review the limitations of current antiarrhythmic drugs in atrial fibrillation (AF) and discuss the rationale and clinical trials supporting the use of ranolazine in AF. Data Sources: MEDLINE was searched from 1980 to September 2016 using the terms ranolazine, atrial fibrillation, coronary artery bypass grafting, and valve surgery. Study Selection and Data Extraction: English-language studies and reviews assessing antiarrhythmic drugs, including ranolazine, were incorporated. Data Synthesis: The use of ranolazine monotherapy has been evaluated in 2 clinical trials. In the RAFFAELLO trial, higher doses of ranolazine showed a trend toward lower AF recurrence versus placebo (P = 0.053), but further evidence is needed to support its use as a sole therapeutic agent. Ranolazine has shown utility in a limited number of studies as an adjunctive agent, which is critical for those in whom standard therapy is inadequate or the adverse event profile precludes optimized standard therapy. In the HARMONY trial, ranolazine 750 mg and dronedarone 225 mg twice daily reduced the AF burden by 59.1% from baseline (P = 0.008 vs placebo). In a trial by Koskinas and colleagues, patients receiving ranolazine 1500 mg once and intravenous amiodarone had a higher conversion rate than those receiving amiodarone alone (P = 0.024). There are also promising studies for the prevention and treatment of post–cardiothoracic surgery AF, which require further investigation. Conclusions: Ranolazine’s pharmacological properties and available evidence suggest potential for its use in AF.

view more

Physical activity intensity and subjective well-being in healthy adults Journal of Health Psychology

Gregory A Panza, Beth A Taylor, Paul D Thompson, C Michael White, Linda S Pescatello


The effect of physical activity intensity on subjective well-being has not been well established. We examined this relationship among 419 healthy adults using objective and subjective physical activity measurements (sample size varied among well-being assessments). For accelerometers, light-intensity physical activity positively associated with psychological well-being (n = 150) and negatively associated with depression (n = 99); moderate intensity negatively associated with pain severity (n = 419) and positively associated with psychological well-being; sedentary behavior negatively associated with psychological well-being and positively associated with depression (ps

view more

The antihypertensive effects of aerobic versus isometric handgrip resistance exercise Journal of Hypertension

Garrett I Ash, Beth A Taylor, Paul D Thompson, Hayley V MacDonald, Lauren Lamberti, Ming-Hui Chen, Paulo Farinatti, William J Kraemer, Gregory A Panza, Amanda L Zaleski, Ved Deshpande, Kevin D Ballard, Mohammadtokir Mujtaba, C Michael White, Linda S Pescatello


Background: Aerobic exercise reduces blood pressure (BP) on average 5–7 mmHg among those with hypertension; limited evidence suggests similar or even greater BP benefits may result from isometric handgrip (IHG) resistance exercise.

view more